Derivatives of an FGFR inhibitor
US12168660B2 · kind B2 · utility
0Cited by
84References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 22, 2022 |
| Grant date | Dec 17, 2024 |
| Priority date | — |
| Expiry date | Feb 9, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to derivatives (e.g., hydroxyl, keto, glucuronide, sulfonic acid, and deuterated) of a Fibroblast Growth Factor Receptors (FGFR) inhibitor, including methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of FGFR mediated disease such as cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.